Pharmaceutical Excipients for Hot-Melt Extrusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Excipients for Hot-Melt Extrusion
The authors examine the influence of glass-transition temperature, melt viscosity, degredation temperature, and process settings.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 74-82

References

1. M.M. Crowley et al., Drug Dev. Ind. Pharm. 33 (9), 909–926 (2007).

2. I. Ghebre-Sellassie and C. Martin, Pharmaceutical Extrusion Technology (Informa Healthcare, New York, Vol. 133, 2007).

3. J. Breitenbach, Eur. J. Pharm. Biopharm. 54 (2), 107–117 (2002).

4. J.E. Patterson et al., Int. J. Pharm. 336 (1), 22–34 (2007).

5. A. Foster, J. Hempenstall, and T. Rades, J. Pharm. Pharmacol. 53 (3), 303–315 (2001).

6. A. Forster et al., Int. J. Pharm. 226 (1–2), 147–161 (2001).

7. J.E. Patterson et al., Drug Dev. Ind. Pharm. 34 (1), 95–106 (2008).

8. S. Janssens et al., Eur. J. Pharm. Sci. 30 (3–4), 288–294 (2007).

9. S. Janssens and G. Van den Mooter, "Enhancing Solubility and Dissolution Rate of Poorly Soluble Drugs," WO 2007/115381, Oct. 2007.

10. E. Karavas et al., Eur. J. Pharm. Biopharm. 63 (2), 103–114 (2006).

11. R.J. Chokshi et al., J. Pharm Sci. 94 (11), 2463–2474 (2005).

12. S. Thumma et al., Eur. J. Pharm. Biopharm. 70 (2), 605–614 (2005).

Citation: When referring to this article, please cite it as "M.Karl, D. Djuric, K.Kolter, "Pharmaceutical Excipients for Hot-Melt Extrusion," Pharmaceutical Technology 35 (5) 74-82 (2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here